Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Within the high-risk cluster, vitamin D3 was lowest, while BMI, triglycerides and BDNF were highest.

Source: Development of multisystem biomarker signatures. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Eighteen blood biomarkers, representing key systems that become dysregulated with ageing, were assessed among n = 4961 participants aged 50+ years from Ireland.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts

Study design awaiting verification · Age and Ageing · 2026

Original publication title

An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts

Belinda Hernández; Eric Klopack; Frank Moriarty; Padraic Fallon; Nollaig Bourke; Eileen Crimmins; Rose-Anne Kenny; Cathal Mc Crory; Aisling O'Halloran

© The Author(s) 2026. Published by Oxford University Press on behalf of the British Geriatrics Society.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

This study provides evidence that biomarker signatures and profiling of disease patterns can be used to risk stratify and identify ageing subpopulations that would benefit most from targeted preventative or secondary intervention strategies.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Global population ageing is progressing at an unprecedented rate. Early identification of subpopulations at risk of chronic diseases could mitigate deteriorating health and increasing health service use, while revealing key biological cues and therapeutic targets. We hypothesised that a multisystem biomarker signature could identify future chronic disease trajectories, multimorbidity, functional decline and mortality.

Source: Background

Abstract: What methods does the paper describe?

Eighteen blood biomarkers, representing key systems that become dysregulated with ageing, were assessed among n = 4961 participants aged 50+ years from Ireland. Probabilistic clustering classified participants as belonging to one of three biomarker signatures at baseline. Biomarker signatures were designated as low, medium and high risk based on relative levels of biomarker dysregulation within the signatures and previously described associations with chronic disease and mortality. These biomarker signatures were utilised to predict 4-year functional decline; 8-year cardiovascular disease (CVD), diabetes, frailty, disability and 12-year mortality.

Results were validated in a US cohort (n = 3914).

Source: Methods

Abstract: Results

Low (58.5%), medium (9.2%) and high-risk (32.3%) biomarker signatures were identified in the cohort from Ireland. The high-risk signature was associated with higher 12-year mortality (HR: 1.89, P < .001); higher 8-year incidence of CVD, diabetes, multimorbidity, frailty and disability (OR range: 1.46 to 2.49. P < .05); and lower 4-year physical function (P < .01). Findings were corroborated in the US cohort. We identified and tracked 6 disease classes over 8 years: healthy, arthritis, diabetes/angina, hypothyroid/osteoporosis/respiratory, vision/anxiety/CVD and multisystem. Associations between the high-risk biomarker signature and two of the five 8-year incident disease classes were observed, implicating dysregulated immune and cardiometabolic pathways.

Source: Results

Abstract: Conclusions

This study provides evidence that biomarker signatures and profiling of disease patterns can be used to risk stratify and identify ageing subpopulations that would benefit most from targeted preventative or secondary intervention strategies.

Source: Conclusions
Authors’ abstract

Abstract

Background

Global population ageing is progressing at an unprecedented rate. Early identification of subpopulations at risk of chronic diseases could mitigate deteriorating health and increasing health service use, while revealing key biological cues and therapeutic targets. We hypothesised that a multisystem biomarker signature could identify future chronic disease trajectories, multimorbidity, functional decline and mortality.

Methods

Eighteen blood biomarkers, representing key systems that become dysregulated with ageing, were assessed among n = 4961 participants aged 50+ years from Ireland. Probabilistic clustering classified participants as belonging to one of three biomarker signatures at baseline. Biomarker signatures were designated as low, medium and high risk based on relative levels of biomarker dysregulation within the signatures and previously described associations with chronic disease and mortality. These biomarker signatures were utilised to predict 4-year functional decline; 8-year cardiovascular disease (CVD), diabetes, frailty, disability and 12-year mortality.

Results were validated in a US cohort (n = 3914).

Results

Low (58.5%), medium (9.2%) and high-risk (32.3%) biomarker signatures were identified in the cohort from Ireland. The high-risk signature was associated with higher 12-year mortality (HR: 1.89, P < .001); higher 8-year incidence of CVD, diabetes, multimorbidity, frailty and disability (OR range: 1.46 to 2.49. P < .05); and lower 4-year physical function (P < .01). Findings were corroborated in the US cohort. We identified and tracked 6 disease classes over 8 years: healthy, arthritis, diabetes/angina, hypothyroid/osteoporosis/respiratory, vision/anxiety/CVD and multisystem. Associations between the high-risk biomarker signature and two of the five 8-year incident disease classes were observed, implicating dysregulated immune and cardiometabolic pathways.

Conclusions

This study provides evidence that biomarker signatures and profiling of disease patterns can be used to risk stratify and identify ageing subpopulations that would benefit most from targeted preventative or secondary intervention strategies.

Publication and source details

Original title: An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts

Belinda Hernández; Eric Klopack; Frank Moriarty; Padraic Fallon; Nollaig Bourke; Eileen Crimmins; Rose-Anne Kenny; Cathal Mc Crory; Aisling O'Halloran

Age and Ageing · 2026

Address correspondence to: Belinda Hernández, The National Center for Pharmacoeconomics (NCPE), St James’s Hospital, Dublin, Ireland. Email: HERNANDB@tcd.ie© The Author(s) 2026. Published by Oxford University Press on behalf of the British Geriatrics Society.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Health Research Board10.13039/100010414 Atlantic Philanthropies10.13039/100004426 Irish Government Health Research Board10.13039/100010414 HRB ILP-PHR-2024-016

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:16:53.222571+00:00

DOI: 10.1093/ageing/afag135 · PMC13189271